Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook

Core Insights - Entera Bio Ltd. is set to submit its final Phase 3 protocol for EB613 to the FDA in Q1 2026, following a favorable ruling in December 2025 [1][3] - The company is advancing its Next-Generation EB613 Phase 1 bridging study, with results anticipated by the end of Q1 2026 [1][4] - Entera is accelerating its oral hypoparathyroidism tablet program with long-acting PTH variants and is engaged in strategic partnership discussions to enhance its pipeline [1][5] Company Overview - Entera Bio is focused on developing oral peptide and protein replacement therapies for significant unmet medical needs, utilizing its proprietary N-Tab™ technology [6] - The company's lead product, EB613, is an oral PTH(1-34) anabolic tablet aimed at post-menopausal women with osteoporosis, having met primary and secondary endpoints in a Phase 2 study [6] - Entera is also developing EB612, an oral long-acting PTH(1-34) peptide tablet for hypoparathyroidism, and other oral peptide therapies targeting obesity and rare malabsorption conditions [6]